封面图片

Direct action antivirals are effective in the total eradication of HCV in renal transplants

<p><strong>Introduction</strong>: The main objective of our study was to analyze the effectiveness of antiviral treatment (conventional or with direct-acting antivirals (DAA)) for total eradication of Hepatitis C Virus (HCV) in kidney transplant (KT) recipients. DAA are known drugs...

Saved in:

书目详细资料
Main Authors:	Teresa Olea (Author), Inmaculada Castillo (Author), Carlos Jiménez (Author), Javier Bartolomé (Author), María José Santana (Author), JA Quiroga (Author), Vicente Carreño (Author), Rafael Selgas (Author)
格式:	图书
出版:	Annals of Antivirals and Antiretrovirals - Peertechz Publications, 2019-07-22.
主题:	Research Article
在线阅读:	Connect to this object online.
标签:	添加标签没有标签, 成为第一个标记此记录!

相似书籍

Impact of HCV antiviral therapy on the Liver Transplantation Waiting-List assessed by mathematical models
由: Eleazar Chaib, et al.
出版: (2019)

Chronic HCV Infection: Clinical Advances and Eradication Perspectives
出版: (2022)

Epidemiological and clinical implications in Kidney Transplantation of occult Hepatitis C virus infection
由: Olea T1, et al.
出版: (2019)

Timing Strategies of Direct-Acting Antivirals and Biologics Administration in HCV-Infected Subjects with Inflammatory Bowel Diseases
由: Nicola Imperatore, et al.
出版: (2017)

Emergence and Persistence of Resistance-Associated Substitutions in HCV GT3 Patients Failing Direct-Acting Antivirals
由: Saima Mushtaq, et al.
出版: (2022)

Immunological Dynamics Associated with Direct-Acting Antiviral Therapies in Naive and Experimented HCV Chronic-Infected Patients
由: Grenda Leite Pereira, et al.
出版: (2019)

HCV-positive kidney transplant patients treated with direct-acting antivirals maintain stable medium-term graft function despite persistent reduction in tacrolimus trough levels
由: Maria Rendina, et al.
出版: (2022)

Effect of sustained virological response after direct-acting antivirals on liver fibrosis in patients with chronic HCV infection
由: Ramy H. Agwa, et al.
出版: (2022)

A study on the prevalence of HCV genotypes and the effect of direct-acting antiviral therapy on clinical and laboratory parameters in HCV-Infected patients at a tertiary care center in North India
由: S Muhammed Shahanas, et al.
出版: (2024)

Direct anti-HCV agents
由: Xingquan Zhang
出版: (2016)

Low plasma levels of BTLA and LAG-3 before HCV therapy are associated with metabolic disorders after HCV eradication in persons with HIV/HCV coinfection: a retrospective study
由: Rubén Martín-Escolano, et al.
出版: (2024)

Future destinations and social inclusion scoping review: how people cured of hepatitis C (HCV) using direct- acting antiviral drugs progress in a new HCV-free world
由: Sarah R. Donaldson, et al.
出版: (2022)

Antiviral therapy of HCV-cirrhosis: case of sequential treatment and review of literature
由: Kakharman Yesmembetov, et al.
出版: (2018)

Management of Hepatitis C Infection with Direct Action Antiviral Drugs (DAA)**
由: Roberto Focaccia, et al.
出版: (2015)

Drug-drug interactions between antithrombotics and direct-acting antivirals in hepatitis C virus (HCV) patients: A brief, updated report
由: Mario Enrico Canonico, et al.
出版: (2022)

Sustained virological response rates with direct-acting antivirals in black subjects with HCV genotype 1 infection: systematic analysis of clinical trials
由: Kimberly Struble, et al.
出版: (2019)

O19 Towards hepatitis C eradication in far North Queensland: a report on models of care and direct acting antiviral outcomes
由: A. Lee, et al.
出版: (2017)

SCORING MODELS FOR PREDICTING HEPATOCELLULAR CARCINOMA RISK IN HCV PATIENTS AFTER ANTIVIRAL THERAPY
由: Oana Irina Gavril, et al.
出版: (2023)

The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: a systematic review and network meta-analysis
由: Ruochan Chen, et al.
出版: (2023)

P29 Treating hepatitis C virus infection (HCV) with direct acting antivirals (DAAs) through the existing infrastructure of opioid agonist therapy (OAT)
由: J. Keats, et al.
出版: (2017)

Facilitators of HCV treatment adherence among people who inject drugs: a systematic qualitative review and implications for scale up of direct acting antivirals
由: Zachary C. Rich, et al.
出版: (2016)

Treatment of HCV with direct-acting antivirals on reducing mortality related to extrahepatic manifestations: a large population-based study in British Columbia, CanadaResearch in context
由: Dahn Jeong, et al.
出版: (2024)

Effectiveness of triple therapy with direct-acting antivirals for hepatitis C genotype 1 infection: application of propensity score matching in a national HCV treatment registry
由: Emma Gray, et al.
出版: (2017)

The epidemiological changes of HCV and HBV infections in the era of new antiviral therapies and the anti-HBV vaccine
由: Cristina Stasi, et al.
出版: (2016)

Role of a clinical pharmacist as part of a multidisciplinary care team in the treatment of HCV in patients living with HIV/HCV coinfection
由: Olea Jr A, et al.
出版: (2018)

Italian Real-World Analysis of the Impact of Polypharmacy and Aging on the Risk of Multiple Drug–Drug Interactions (DDIs) in HCV Patients Treated with Pangenotypic Direct-Acting Antivirals (pDAA)
由: Fagiuoli S, et al.
出版: (2023)

Updated View on Kidney Transplant from HCV-Infected Donors and DAAs
由: Fabrizio Fabrizi, et al.
出版: (2021)

Efficacy and safety of direct-acting antivirals for treatment of hepatitis C infected kidney transplant recipients; a meta-analysis
由: Wisit Cheungpasitporn, et al.
出版: (2017)

P49 MAGELLAN-1, PART 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic HCV genotype 1 or 4 and prior direct-acting antiviral treatment failure
由: Fred Poordad, et al.
出版: (2017)

Effectiveness of oral direct antiviral agents against chronic hepatitis C virus infection for HIV/HCV co-infected patients: a success story from a prospective cohort
由: Guillaume Laurichesse, et al.
出版: (2016)

Virus infection and direct-acting antivirals in pregnancy
由: Xuan Huang, et al.
出版: (2022)

Repurposing Antifungals for Host-Directed Antiviral Therapy?
由: Sebastian Schloer, et al.
出版: (2022)

Sofosbuvir as a drug in recurrent HCV therapy occurring after liver transplantation
由: Katarzyna Lipa, et al.
出版: (2018)

Sofosbuvir as a drug in recurrent HCV therapy occurring after liver transplantation
由: Katarzyna Lipa, et al.
出版: (2018)

Direct Acting Antivirals in Hepatitis C-Infected Kidney Transplant Recipients: Associations with Long-term Graft Failure and Patient Mortality
由: Michael R Goetsch, et al.
出版: (2020)

An in vitro study of an Artocarpus heterophyllus substance as a hepatitis C antiviral and its combination with current anti-HCV drugs
由: Adita Ayu Permanasari, et al.
出版: (2021)

Beneficial Effects of Silybin Treatment After Viral Eradication in Patients With HCV-Related Advanced Chronic Liver Disease: A Pilot Study
由: Valentina Cossiga, et al.
出版: (2022)

Direct-acting Antivirals in Kidney Transplant Patients: Successful Hepatitis C Treatment and Short Term Reduction in Urinary Protein/Creatinine Ratios
由: Michael R. Goetsch, et al.
出版: (2017)

IP-10 Interferes With the Antiviral Response of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection
由: Yadong Wang, et al.
出版: (2022)

P28 Queensland injectors health network (QuIHN) treatment management program (TMP): hepatitis C virus (HCV) direct acting antivirals (DAA) full access for people who inject drugs
由: R. Kavanagh, et al.
出版: (2017)